265 related articles for article (PubMed ID: 22234741)
1. Sclerostin: therapeutic horizons based upon its actions.
Costa AG; Bilezikian JP
Curr Osteoporos Rep; 2012 Mar; 10(1):64-72. PubMed ID: 22234741
[TBL] [Abstract][Full Text] [Related]
2. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
[TBL] [Abstract][Full Text] [Related]
3. Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions.
Weivoda MM; Oursler MJ
Curr Osteoporos Rep; 2014 Mar; 12(1):107-14. PubMed ID: 24477413
[TBL] [Abstract][Full Text] [Related]
4. Sclerostin and skeletal health.
Sharifi M; Ereifej L; Lewiecki EM
Rev Endocr Metab Disord; 2015 Jun; 16(2):149-56. PubMed ID: 25669441
[TBL] [Abstract][Full Text] [Related]
5. Update on romosozumab : a humanized monoclonal antibody to sclerostin.
Costa AG; Bilezikian JP; Lewiecki EM
Expert Opin Biol Ther; 2014 May; 14(5):697-707. PubMed ID: 24665957
[TBL] [Abstract][Full Text] [Related]
6. Anti-sclerostin - is there an indication?
Larsson S
Injury; 2016 Jan; 47 Suppl 1():S31-5. PubMed ID: 26768288
[TBL] [Abstract][Full Text] [Related]
7. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.
Sebastian A; Loots GG
Metabolism; 2018 Mar; 80():38-47. PubMed ID: 29080811
[TBL] [Abstract][Full Text] [Related]
8. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.
van Bezooijen RL; ten Dijke P; Papapoulos SE; Löwik CW
Cytokine Growth Factor Rev; 2005 Jun; 16(3):319-27. PubMed ID: 15869900
[TBL] [Abstract][Full Text] [Related]
9. Identification of the disease-causing gene in sclerosteosis--discovery of a novel bone anabolic target?
Balemans W; Van Hul W
J Musculoskelet Neuronal Interact; 2004 Jun; 4(2):139-42. PubMed ID: 15615113
[TBL] [Abstract][Full Text] [Related]
10. [Anti-sclerostin antibody : its bone formation effect and therapeutic potential for osteoporosis].
Endo I
Clin Calcium; 2014 Jan; 24(1):69-73. PubMed ID: 24369282
[TBL] [Abstract][Full Text] [Related]
11. Sclerostin: clinical insights in muscle-bone crosstalk.
Moretti A; Iolascon G
J Int Med Res; 2023 Aug; 51(8):3000605231193293. PubMed ID: 37632438
[TBL] [Abstract][Full Text] [Related]
12. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
Clarke BL
Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
[TBL] [Abstract][Full Text] [Related]
13. Role and mechanism of action of sclerostin in bone.
Delgado-Calle J; Sato AY; Bellido T
Bone; 2017 Mar; 96():29-37. PubMed ID: 27742498
[TBL] [Abstract][Full Text] [Related]
14. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders.
Marini F; Giusti F; Palmini G; Brandi ML
Osteoporos Int; 2023 Feb; 34(2):213-238. PubMed ID: 35982318
[TBL] [Abstract][Full Text] [Related]
15. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.
Li X; Ominsky MS; Niu QT; Sun N; Daugherty B; D'Agostin D; Kurahara C; Gao Y; Cao J; Gong J; Asuncion F; Barrero M; Warmington K; Dwyer D; Stolina M; Morony S; Sarosi I; Kostenuik PJ; Lacey DL; Simonet WS; Ke HZ; Paszty C
J Bone Miner Res; 2008 Jun; 23(6):860-9. PubMed ID: 18269310
[TBL] [Abstract][Full Text] [Related]
16. Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin.
Sato AY; Cregor M; Delgado-Calle J; Condon KW; Allen MR; Peacock M; Plotkin LI; Bellido T
J Bone Miner Res; 2016 Oct; 31(10):1791-1802. PubMed ID: 27163932
[TBL] [Abstract][Full Text] [Related]
17. Sclerostin: from bench to bedside.
Tanaka S; Matsumoto T
J Bone Miner Metab; 2021 May; 39(3):332-340. PubMed ID: 33206222
[TBL] [Abstract][Full Text] [Related]
18. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.
Kedlaya R; Veera S; Horan DJ; Moss RE; Ayturk UM; Jacobsen CM; Bowen ME; Paszty C; Warman ML; Robling AG
Sci Transl Med; 2013 Nov; 5(211):211ra158. PubMed ID: 24225945
[TBL] [Abstract][Full Text] [Related]
19. Sclerostin: recent advances and clinical implications.
Honasoge M; Rao AD; Rao SD
Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):437-46. PubMed ID: 25333305
[TBL] [Abstract][Full Text] [Related]
20. An Additional Lrp4 High Bone Mass Mutation Mitigates the Sost-Knockout Phenotype in Mice by Increasing Bone Remodeling.
Hendrickx G; Boudin E; Mateiu L; Yorgan TA; Steenackers E; Kneissel M; Kramer I; Mortier G; Schinke T; Van Hul W
Calcif Tissue Int; 2024 Feb; 114(2):171-181. PubMed ID: 38051321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
